'NEW mRNA RSV 'vaccine' PINGHeck no! From the article below - Moderna, Pfizer, fast-tracked, new mRNA injection!
Both COVID “Vaccines” & RSV “Vaccines” cause ADE & you’re more likely to get severe COVID & RSV after Vaccination
expose-news.com ^ | February 10, 2023 | Rhoda WilsonPosted on 11/25/2023, 10:01:08 PM by ransomnote
EXCERPT BELOW:
Pharma thinks we need a “vaccine” for every illness, even if it shows up in most people as a mild cold. This latest one has been granted fast-track designation, meaning it will skip the usual scrutiny, just like the covid injections did. Get ready for the fear-mongering so people will roll up their sleeves again.
Moderna just moved one step closer to bringing mRNA-1345, an RSV injection, to market. The US Food and Drug Administration (“FDA”) granted the experimental injection fast-track designation in August 2021. Moderna’s mRNA RSV injection has now been given Breakthrough Therapy Designation, which allows for faster development and an expedited review period.
RSV is usually not serious; most people experience only mild, cold-like symptoms and recover on their own in a week or two.
Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023. Along with Moderna’s mRNA RSV injection, Pfizer and GSK have also developed RSV vaccines that are awaiting regulatory approval.
In the General/Chat forum, on a thread titled opinions on RSV Vaccine for Adults, ransomnote wrote: 'NEW mRNA RSV 'vaccine' PINGHeck no! From the article below - Moderna, Pfizer, fast-tracked, new mRNA injection!
Both COVID “Vaccines” & RSV “Vaccines” cause ADE & you’re more likely to get severe COVID & RSV after Vaccination
expose-news.com ^ | February 10, 2023 | Rhoda WilsonPosted on 11/25/2023, 10:01:08 PM by ransomnote
EXCERPT BELOW:
Pharma thinks we need a “vaccine” for every illness, even if it shows up in most people as a mild cold. This latest one has been granted fast-track designation, meaning it will skip the usual scrutiny, just like the covid injections did. Get ready for the fear-mongering so people will roll up their sleeves again.
Moderna just moved one step closer to bringing mRNA-1345, an RSV injection, to market. The US Food and Drug Administration (“FDA”) granted the experimental injection fast-track designation in August 2021. Moderna’s mRNA RSV injection has now been given Breakthrough Therapy Designation, which allows for faster development and an expedited review period.
RSV is usually not serious; most people experience only mild, cold-like symptoms and recover on their own in a week or two.
Moderna plans to file for FDA approval of mRNA-1345 in the first half of 2023. Along with Moderna’s mRNA RSV injection, Pfizer and GSK have also developed RSV vaccines that are awaiting regulatory approval.